Patents by Inventor Bob D. Brown

Bob D. Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 11873493
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: January 16, 2024
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION
    Publication number: 20230365974
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Application
    Filed: January 18, 2023
    Publication date: November 16, 2023
    Inventors: Bob D. Brown, Natalie PURSELL, Henryk T. DUDEK, Cheng LAI
  • Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA
    Patent number: 11773390
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: October 3, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 EXPRESSION
    Publication number: 20230287425
    Abstract: Oligonucleotides are provided herein that inhibit angiopoietin-like protein 3 (ANGPTL3) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with ANGPTL3 expression.
    Type: Application
    Filed: March 18, 2021
    Publication date: September 14, 2023
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Marc ABRAMS, Anton TURANOV
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
    Patent number: 11697812
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: July 11, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
    Patent number: 11667918
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing AT3 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: June 6, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for inhibiting expression of LDHA
    Patent number: 11661604
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: May 30, 2023
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA
    Publication number: 20230111150
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
    Type: Application
    Filed: August 25, 2022
    Publication date: April 13, 2023
    Inventor: Bob D. Brown
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20230069235
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 2, 2023
    Inventors: Bob D. BROWN, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA
    Publication number: 20230058834
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: July 1, 2021
    Publication date: February 23, 2023
    Inventors: Bob D. BROWN, Henryk T. DUDEK
  • Compositions and methods for inhibiting GYS2 expression
    Patent number: 11572562
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: February 7, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Natalie Pursell, Henryk T. Dudek, Cheng Lai
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20220396799
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 15, 2022
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Cheng LAI
  • Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
    Patent number: 11447777
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: September 20, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob D. Brown
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 11359203
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: June 14, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Methods and compositions for inhibiting expression of LDHA
    Patent number: 11286488
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 29, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11208658
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: December 28, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA
    Publication number: 20210230604
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: January 25, 2021
    Publication date: July 29, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double stranded RNA
    Patent number: 11066672
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: July 20, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 11060093
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: July 13, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 11053502
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai